Companies /Healthcare

Johnson & Johnson

NYSE: JNJ Drug Manufacturers - General
$283.62
▲ $3.21 (+1.14%) today
Markets closed · 6:26pm ET

24/7 Wall St. View

Price Prediction $307.42 +8.4% Our analysts’ 12-month view: target, optimistic case, and floor. JNJ price prediction → Earnings EPS vs. the estimate, revenue, and how the market reacted. JNJ earnings history →

JNJ at a Glance

Valuation
Market cap
$675.0B
P/E ratio
42.6
Dividend yield
1.88%
Profitability
Revenue (TTM)
$99.3B
Profit margin
16.2%
EPS (TTM)
$6.59
Price
52-week range
$189 – $283
24/7 target
$307.42
Street target
$279.41
Earnings
Next report
Jan 26, 2027

Headquartered in New Brunswick, NJ Fiscal year ends December NYSE: JNJ jnj.com

About Johnson & Johnson

Johnson & Johnson is a global healthcare company operating through two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops and commercializes therapies across oncology (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT/LAZCLUZE, ERLEADA, IMBRUVICA), immunology (TREMFYA, STELARA, SIMPONI/SIMPONI ARIA, REMICADE), neuroscience (SPRAVATO, CAPLYTA, INVEGA SUSTENNA/XEPLION/INVEGATRINZA/TREVICTA, CONCERTA), pulmonary hypertension (OPSUMIT/OPSYNVI, UPTRAVI), infectious diseases (EDURANT, PREZISTA/SYMTUZA), and cardiovascular/metabolism (XARELTO). The MedTech segment encompasses cardiovascular devices (electrophysiology products, Abiomed heart support, Shockwave intravascular lithotripsy), surgical instruments and solutions (advanced and general surgery), vision care (contact lenses and surgical ophthalmology), and orthopaedics (hips, knees, trauma, spine, and sports medicine). The company is in the process of planning a separation of its Orthopaedics business. Johnson & Johnson trades on the NYSE under the ticker JNJ and serves healthcare professionals and patients in markets worldwide. Updated

Latest Activity

CNBC's "Fast Money"
PodcastCNBC's "Fast Money"Melissa Lee · 44 min

Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge

  • Jensen Huang's exit leaves Nvidia down nearly a third from its $6 trillion peak, with the vendor-financing web in question
  • DA Davidson's Gil Lauria keeps a Buy but cuts his target to $200, preferring AMD, Broadcom and Micron near term
  • 10-year yields above 5.1% make neocloud financing costlier; NScale's S1 shows $5.5B of debt
  • Apple at 39x forward earnings framed as a Costco- or Walmart-style safe haven

Capital is rotating within the AI trade, moving from the Nvidia complex toward AMD and Micron, while Apple gets priced like a staple on 90% iPhone loyalty and almost no AI capex. The pressure point is funding costs, with debt-heavy neocloud borrowers the first to feel a higher 10-year yield.

Read more
Mad Money w/ Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 11/11/26

  • Cramer says Nvidia leadership turmoil has made him gun shy on tech, yet writing off data center names risks big upside
  • CoreWeave CEO: compute demand 10 times oversubscribed for 2027, with chips recontracting at 20% to 50% premiums
  • Cramer would rather own Colgate or Johnson & Johnson than chase the noise right now
  • Caller questions on Darden's Olive Garden value proposition, Meta re-entry, and Jersey Mike's under Charlie Morrison

The tell is that four-year-old GPUs are being recontracted above their original prices, which undercuts the view that AI hardware depreciates into worthlessness. Cramer is keeping data center exposure in semis, networking, turbines and cooling even while trimming elsewhere, and he is leaning defensive with staples and pharma as the Nvidia story gets messier.

Read more
Bloomberg Businessweek
PodcastBloomberg BusinessweekCarol Massar · 29 min

AI Rally Sets Emerging Stocks Up for Best Streak Since September

  • Bloomberg's Brody Ford: CoreWeave eased financing fears via customer prepayments and vendor financing, likely from Nvidia
  • Even after the jump, CoreWeave remains down more than 66% from its highs
  • Anthropic's IPO is already multiple times oversubscribed, with bankers weighing a $1.5 trillion valuation
  • J&J backed psychedelic-inspired biotech Delics with a $100 million oversubscribed round

The relief rally in CoreWeave rests on creative funding: prepayments and vendor financing bought time, and the stock is still more than 66% below its highs. Anthropic's oversubscribed IPO book at a $1.5 trillion valuation is the next read on how much AI spending the market will underwrite.

Read more
JNJJohnson & Johnson
52-week high
$282.11
+1.32%vs prior 52-week high · Sep 3, 2026

Johnson & Johnson closed at $282.11, clearing its September 3 peak by 1.32%. Gilead and AbbVie also finished higher.

Related stockstoday
  • GILDGilead SciencesPartner+1.5%
    Feb 24, 4:18 PM ET · SEC 10-K
  • ABBVAbbViePartner+0.7%
    Feb 11, 4:06 PM ET · SEC 10-K
  • TAKTakeda PharmaceuticalPartner+0.4%
    Jun 17, 6:06 AM ET · SEC 10-K

Moves: Nov 9, 2026 · Alpha Vantage daily close

4 more related stocks · 1 has no US listing

Read more
Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 10/26/26

  • Cramer's bear case: a flood of IPOs and secondaries, $148B raised so far this year, drains the money that funds stocks
  • Applied Materials down from $739 to $387: buy 25 shares now, add on the pattern, finish in the 200s
  • Moderna after a parabolic move: let it come in before earnings, no buying parabolic charts
  • Thermo Fisher CEO on a beat-and-raise, BlackBerry's turnaround, and CrowdStrike cyber worries on deck

The call that matters for holders here is supply: Cramer argues the equity and debt markets are nearly tapped out after Meta, Alphabet and SpaceX raisings, with Anthropic's S1 now in line. He stops short of calling a top while pushing for buybacks and takeovers over further deals, favoring staged buying in Applied Materials and patience on Moderna.

Read more
Jim Cramer
PodcastMad Money w/ Jim CramerJim Cramer · 44 min

Mad Money w/ Jim Cramer 10/13/26

  • Semis called the market's ball and chain: the VanEck chip ETF fell 7.22% over six sessions, its worst streak since May of last year
  • Cramer says Micron's China memory fears are overblown, pointing to 26 long-term take-or-pay contracts running to 2030
  • Apple stays a buy into the foldable two-screen iPhone, with new Siri devices driving memory and CPU demand
  • Wells Fargo should have been a winner on Charlie Scharf's rate-sensitive setup and next-year guidance

The call is to ignore the chip tape and look at where the silicon actually goes: Cramer argues Micron and AMD demand is real even as Korean memory pricing drags the whole group lower. He also thinks the bank selloff mispriced Wells Fargo, which makes more money if rates keep climbing.

Read more
JNJJohnson & Johnson
Regular session
$245.87
-3.38%open $254.46

A 3.4% slide to $245.87 is an outsized single day for a $592 billion defensive name, and it lands with earnings due today. The report arrives with the stock already repriced.

Read more
JNJJohnson & Johnson
Reports Tue Oct 13Before openConfirmed

Johnson & Johnson reports at 6:20 AM ET with consensus at $2.50 in EPS on $25.38 billion in revenue. The guidance commentary on talc settlement costs and device demand is what moves the stock.

    Read more
    Earnings on deck — Oct 12–16
    51 companies38 before open13 after close

    Q3 earnings season front-loads everything into two mornings: JPMorgan, Goldman, Wells Fargo, Citi, UnitedHealth and Johnson & Johnson all report before the open Tuesday, with Bank of America, Morgan Stanley, BlackRock and ASML following Wednesday. Of 51 companies on the week, 38 land before the bell, so the tone for rates, credit and chip demand gets set early.

    • UNHUnitedHealth Group IncorporatedTue Oct 13Before open
    • JPMJPMorgan Chase & Co.Tue Oct 13Before open
    • GSThe Goldman Sachs Group, Inc.Tue Oct 13Before open
    • WFCWells Fargo & CompanyTue Oct 13Before open
    • DPZDomino's Pizza, Inc.Tue Oct 13Before open
    • JNJJohnson & JohnsonTue Oct 13Before open
    • CCitigroup Inc.Tue Oct 13Before open
    • ACIAlbertsons Companies, Inc.Tue Oct 13Before open
    • FBKFB Financial CorporationTue Oct 13Before open
    • AZZAZZ Inc.Tue Oct 13After close
    • ASMLASML Holding N.V.Wed Oct 14Before open
    • BACBank of America CorporationWed Oct 14Before open
    • MSMorgan StanleyWed Oct 14Before open
    • BLKBlackRock, Inc.Wed Oct 14Before open
    • PGRProgressive CorporationWed Oct 14Before open
    Read more
    Jim Cramer
    PodcastMad Money w/ Jim CramerJim Cramer · 44 min

    Mad Money w/ Jim Cramer 10/5/26

    • Cramer flags a broken pattern: oil fell while the 30-year yield climbed to 5.66%, near 6%
    • Nasdaq's record close carried by Microsoft on Copilot, Meta's small-business ad shift, and Nvidia's all-time high
    • Saudis discounting crude $5 below the Oman/Dubai benchmark is market share defense, not a fading war premium
    • Caller questions on Intuitive Surgical as a broken stock, plus KLA, Domino's and SoFi

    Cramer's warning: strip out Microsoft, Nvidia and Meta and the safety names were hit, meaning three stocks are carrying the index. He says the bond market tells the truth longer term, and the 30-year at 5.66% caps any broad rally. Owning the hyperscalers has been the only trade that worked.

    Read more

    JNJ Coverage

    Load More

    Frequently Asked Questions

    What does Johnson & Johnson do?

    Johnson & Johnson is a global healthcare company operating through two business segments: Innovative Medicine and MedTech.

    What is the JNJ stock price target?

    24/7 Wall St.'s 12-month price target for JNJ is $307.42, rated Buy. The Wall Street consensus target is $279.41. JNJ price prediction →